Bradykinin and high glucose promote renal tubular inflammation
Sydney Tang(Chinese University of Hong Kong), K.N. Lai(Queen Mary Hospital)
Cited by 75
Related Papers
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
|The Lancet|2023|264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
|The Lancet|2023|214
Mesenchymal Stem Cells Modulate Albumin-Induced Renal Tubular Inflammation and Fibrosis
|PLoS ONE|2014|80